Abstract. Fragments representing the genes of the two major outer membrane proteins of spotted fever group rickettsiae (rOmpA and rOmpB) were tested as DNA vaccines. Immunizations with each of three fragments (rompA , rompB , and rompB ) conferred a degree of protection on vaccinated mice against virulent rickettsial challenge. Protection was achieved when DNA immunizations were followed by booster immunizations with the homologous recombinant protein. Proliferation and gamma-interferon secretion were detected after in vitro stimulation of lymphocytes from immunized animals with whole Rickettsia conorii antigen. The data validate particular segments of rOmpA and rOmpB as potent immunogens and hence as sources of immunostimulatory elements with specificity for T lymphocytes, which are the key effectors of protective immunity against rickettsial infections.
INTRODUCTION
Rickettsiae of the spotted fever group (SFG) are obligately intracellular bacteria that are transmitted by the bite of infected ticks or mites. Immediately after injection via the arthropod saliva into the skin, rickettsiae grow initially in undetermined cell types in the bite site and apparently spread via the lymphatic vessels to regional lymph nodes where they multiply prior to spreading to the blood stream and infecting the endothelium throughout the body. Infection of the endothelium causes vascular damage leading to increased vascular permeability, edema, hypovolemia and hypotension. [1] [2] [3] Both humoral and T cell mediated immune responses follow infection. After recovery, immunity is solid and long lasting, no human reinfections have been reported, and experimental animals that have recovered from SFG rickettsioses are solidly immune to rechallenge. The mechanisms of protective immunity, however, are incompletely understood. T cell-mediated responses are considered more crucial than humoral immunity. [4] [5] [6] [7] ϩ T lymphocytes play an important role in the ultimate immune clearance of rickettsiae from the endothelium. 8 The intracellular killing process is known to be mediated in mice by gamma-interferon (IFN-␥), tumor necrosis factor-alpha, and nitric oxide. 9, 10 Currently, there is no effective vaccine against any SFG rickettsia, and despite the availability of effective antimicrobial therapy, mortality occurs among patients hospitalized with Rocky Mountain spotted fever (RMSF) and boutonneuse fever. [11] [12] [13] There have been three attempts to develop a vaccine against RMSF. These vaccine preparations consisted of killed rickettsiae prepared from infected ticks, 14 yolk sac of embryonated chicken eggs, 15 and cell culture. 16 All three vaccines failed to prevent disease, and in some cases vaccinees developed severe local reactions at the immunization site. [16] [17] [18] Development of a vaccine against RMSF and boutonneuse fever, especially for the endemic areas, would be a significant addition to the armamentarium of preventive medicine against these life-threatening, diagnostically difficult diseases. Recent advances in molecular biology and the availability of improved and more sensitive immune assays have been instrumental in the ongoing process of identifying the key elements needed for stimulating protective immunity. The two major outer membrane proteins of SFG rickettsiae, rOmpA and rOmpB, have been identified as major immunogenic antigens. rOmpA has an apparent molecular mass of 150-190 kD (based on its electrophoretic mobility by sodium dodecyl sulfate-polyacrylamide gel electrophoresis) and is divided into four domains based on the deduced protein sequence and relative hydrophobicity. 19 Domain II consists of tandem repeat units starting at amino acid residue 212. The domain II of Rickettsia conorii varies from a content of six to 15 repeat units. 20 The repeat region of R. rickettsii contains 13 repeat units consisting of highly related sequences of 225 or 216 nucleotides each. 19 This repeat unit domain has been hypothesized to be involved in rickettsial adhesion. 21, 22 The deduced protein sequence for the carboxy terminal is non-repetitive and is more hydrophilic than the repeat region, suggesting possible sites for surface-exposed epitopes.
rOmpB has a molecular mass of approximately 135 kD. [23] [24] [25] [26] It is encoded as a 168-kD protein that includes a putative ␤-autotransporter and undergoes post-translational processing to its mature 135-kD form. 27 rOmpB of the typhus group rickettsiae has been referred to as a surface protein antigen (SPA) and is thought to form part of an S-layer. 28 rOmpA and rOmpB elicit both humoral and T cell-mediated immune responses. The majority of monoclonal antibodies from mice inoculated with SFG rickettsiae react with heat-stable or heat-labile epitopes present on these two proteins or with the cell wall lipopolysaccharide. [29] [30] [31] In addition, T cell clones have been developed against epitopes of each protein, indicating the presence of both CD8 and CD4 epitopes (Feng HM, Walker DH, unpublished data). Immunization with recombinant rOmpA of R. rickettsii protects guinea pigs solidly against a lethal dose of R. rickettsii. 32 Moreover, immunization with recombinant rOmpA of R. conorii completely protects guinea pigs against challenge with R. conorii and partially protects against challenge with R. rickettsii. 33 Immunization with native rOmpB of R. typhi has been shown to completely protect mice 34 and partially protect guinea pigs against a lethal dose of R. typhi. 35 All these findings support rOmpA and rOmpB as potential vaccine candidates; however, a better candidate would be a vaccine that contains only the antigens that strongly stimulate the arms of the immune system that are relevant for the clearance of rickettsial infections, particularly CD8 and CD4 T lymphocytes. Thus, the objective of this study was the -3Ј  5Ј-ATGGCGGCTAATTCGGTTGGTGA-3Ј  5Ј-ATGAATGTTGCGGTGACAAATAA-3Ј  5Ј-ATGGTCGGTGGACAGCAAGGTAATAAG-3Ј   5Ј-AGAAAGTACTAAAACAGAATC-3Ј  5Ј-CCGACACCGACATCAAAACTT-3Ј  5Ј-ACTACGTTACCGGGACCAGAAA-3Ј  5Ј-GGTAACGATAGCTCCAACAAAG-3Ј identification of the T lymphocyte immunostimulatory fragments present in rOmpA and rOmpB that confer protection against a lethal challenge with R. conorii. Three fragments, rompA , rompB , and rompB 2459-4123 , were able to stimulate some degree of protection against virulent rickettsial challenge. Protection was better achieved when DNA immunizations were followed by booster immunizations with the homologous recombinant protein.
MATERIALS AND METHODS
Rickettsia. R. conorii (Malish 7 strain), a human isolate from South Africa, was obtained from the American Type Culture Collection (ATCC, Rockville, MD) and cultivated in specific pathogen-free embryonated chicken eggs. Rickettsial suspensions were prepared by homogenization of infected yolk sacs using a Waring blender and diluted to a 10% suspension in sucrose-phosphate-glutamate buffer (SPG; 218 mM sucrose, 3.8 mM KH 2 PO 4 , 7.2 mM K 2 HPO 4 , 4.9 mM monosodium L-glutamic acid, pH 7.0). Aliquots of the stock were kept frozen at Ϫ80ЊC. Particulate rickettsial antigen was prepared by renografin density gradient purification from infected Vero cells (African green monkey kidney cells; ATCC). 36 After purification, rickettsiae were killed by exposure to 100ЊC for 10 min.
Plasmid DNA constructs. rOmpA fragments were amplified by a polymerase chain reaction (PCR) from the plasmid vector pBA13 (Table 1) . pBA13, a generous gift from Burt Anderson, 19 contains the majority of the open reading frame (ORF) for rOmpA of R. rickettsii (Genbank accession #M31227). rOmpB fragments were PCR-amplified from p120R-19 (Table 1) , a generous gift from Robert Gilmore. 37 p120R-19 contains the majority of the ORF for rOmpB of R. rickettsii (Genbank accession #X16353). Rickettsia rickettsii and R. conorii share homology of both rompA and rompB genes of greater than 95%. Fragments were ligated to the mammalian expression vector backbone pcDNA3.1/ V5/His-TOPO (Invitrogen, Carlsbad, CA) and transformed into competent Escherichia coli TOP 10F' cells according to the manufacturer's instructions. Transformants bearing plasmids containing rickettsial DNA fragments were identified by restriction endonuclease analysis. Orientation and frame relative to the cytomegalovirus (CMV) promoter and His tag were confirmed by automated DNA sequence analysis using an ABI Prism 377 DNA sequencer (Perkin Elmer Applied Biosystems, Foster City, CA). All plasmid constructs were maintained in the E. coli transformants under ampicillin selection, and large-scale concentrated plasmid preparations (1.5-2.5 mg/ml) of these constructs were generated using EndoFree Plasmid Mega Kits (Qiagen, Valencia, CA) according to the manufacturer's instructions.
Protein purification. Recombinant proteins encoded by each one of the rickettsial gene fragments were prepared. Two prokaryotic expression systems were used. The first one used the pGEX system (Amersham Pharmacia Biotech, Piscataway, NJ). The desired DNA fragments were generated by restriction enzyme digestion and cloned into the pGEX plasmid backbone. Transformation into competent E. coli BL21 cells was carried out following standard procedures. Correct frame and orientation were confirmed by automated DNA sequence analysis. Single colonies of transformed E. coli were picked and grown in 2ϫ YT-G medium (1.6% tryptone, 1% yeast extract, 0.085 M NaCl, and 2% glucose, pH 7.0) with 100 g/ml of ampicillin. Expression was induced using 0.1 mM isopropyl-␤-D-thiogalactopyranoside (IPTG) when the culture reached an absorbance at 260 nm (A 600 ) of 1.5-2.0. After induction, cells were incubated at 37ЊC for 4 hr. Subsequently, the cells were pelleted and lysed by freezing/thawing and sonication. The lysate was incubated with glutathione sepharose beads. Recombinant glutathione-S-transferase (GST)-fusion rickettsial proteins bound to the glutathione beads. The beads were washed thoroughly to eliminate other contaminant proteins and were kept at 4ЊC in phosphate-buffered saline until used for immunization. The levels and quality of expression obtained using this system varied from preparation to preparation. In addition, GST controls showed high background stimulation of lymphocyte proliferation in some in vitro antigen-stimulation experiments. For these reasons, the pCRT7/CT-TOPO (Invitrogen) expression system was used subsequently. This system uses the same cloning strategies as the mammalian expression vector pcDNA3.1/V5/His-TOPO (Invitrogen). With this system, proteins are expressed as a fusion protein containing six consecutive histidine residues (6ϫHis tag). After transformation, frame and orientation were confirmed by automated DNA sequencing analysis. Plasmids were maintained as E. coli TOP10'F transformants. For expression and purification of recombinant proteins, competent E. coli BL21 cells were transformed with each plasmid construct. The culture was incubated overnight in a volume of 10 ml under ampicillin selection (100 g/ml), and 500 ml of fresh LB medium containing 100 g/ml of ampicillin were inoculated with the overnight culture. The culture was incubated with vigorous shaking until reaching an A 600 of 1.5-2.0. IPTG (0.1 mM) was added to induce expression. Flasks were incubated for an additional 4 hr. After induction, cells were pelleted and kept frozen at Ϫ80ЊC overnight. The pellet was thawed for 15 min and resuspended in lysis buffer (100 mM NaH 2 PO 4 , 10 mM Tris-Cl, 8 M urea, pH 8.0). The solution was stirred for 1 hr at room temperature until it became translucent. The lysate was centrifuged at 10,000 ϫ g for 30 min at room temperature to pellet cellular debris, and the 
rompA 4999 #4 (n ϭ 6) #5 (n ϭ 6) pcDNA rHis R. conorii supernatant fluid was collected. Proteins were purified using an Ni-NTA spin kit (Qiagen). This system uses nickel-nitriloacetic acid (Ni-NTA) metal affinity chromatography matrices for proteins that contain a 6ϫHis tag. Purification was carried out according to the manufacturer's instructions. Recombinant proteins were separated in a sodium dodecyl sulfate-polyacrylamide gel, transferred to a nylon membrane and detected with an anti-6ϫHis-tag antibody conjugated to alkaline phosphatase (Invitrogen). Mice, immunizations, and challenge. The maintenance and care of experimental animals complied with the National Institutes of Health guidelines for the humane use of laboratory animals. Three sets of immunization experiments were carried out ( Table 2 ). Six to eight-week old male C3H/ HeN mice (Hartley Sprague-Dawley, Indianapolis, IN) were used in all three experiments. Mice were provided unrestricted access to food and water. During the first experiment, animals received three immunizations with 100 g of plasmid DNA mixed with 100 g of pWRG/mIL-12 (pIL-12). Plasmid interleukin-12 (pIL-12) is a pBluescript plasmid (Stratagene, La Jolla, CA) that encodes the two subunits of murine interleukin-12, p40 and p35. Both subunits are under separate CMV promoter regions and bovine growth hormone poly A signal. pIL-12 was kindly provided by Dr. Hua Yu (Moffitt Cancer Center, Tampa, FL). The first two DNA immunizations were administered intramuscularly in the tibialis anterior muscles four weeks apart. A third DNA immunization was administered subcutaneously using a Biojector (Bioject, Inc., Portland, OR). A Biojector is a needle-free device that uses compressed CO 2 to inject fluids. Half of the mice that received DNA immunizations also received two subcutaneous booster immunizations of the homologous purified recombinant protein (100 g) each four weeks apart. Control groups included mice vaccinated with non-recombinant vector, non-recombinant vector plus GST, saline only, or a sublethal dose of R. conorii.
For the second experiment, animals were immunized with only two doses of DNA (100 g of recombinant plasmid and 100 g of pIL-12) four weeks apart given intramuscularly in the tibialis anterior muscles. An additional fragment (rompB 1550-2739 ) that was not available for the first experiment was included. All mice that received DNA immunizations were also administered two booster immunizations of 100 g each of the homologous purified recombinant protein.
Three groups that received only the two immunizations with one of the three recombinant proteins of rOmpA or rOmpB (without DNA vaccination) were included in this experiment. Control mice received either non-recombinant vector plus ␤-galactosidase-His recombinant protein (negative control) or a sublethal immunizing dose of R. conorii (positive control).
During the third experiment, animals received a mixture of four plasmids containing the fragments rompA 4999-6710 , rompB , and rompB ; the fragment rompA 2176-3933 was also included. Half of the mice immunized with the DNA mixture received two booster immunizations containing a mixture of the homologous recombinant proteins. A group that received only the recombinant protein mixture was included. Positive and negative control groups were the same as in experiment two. All mice immunized with recombinant protein preparations received 300 g of the antihistaminic drug Promethazine (Elkins-Sinn, Cherry Hill, NJ) subcutaneously prior to the challenge to prevent an anaphylactic response to the inoculum.
Mice were challenged with 3 median lethal doses (LD 50 ) of R. conorii. In a previous experiment, this dose was shown to kill 100% of naive mice. After challenge, animals were observed daily for morbidity and mortality. Data were analyzed using Fisher's exact test. Differences between data sets were termed significant if P Ͻ 0.05.
Lymphocyte responses. T lymphocyte responses were determined by measurement of cell proliferation and IFN-␥ secretion after antigen stimulation. The standard thymidine incorporation assay was used to quantify lymphocyte proliferation. Briefly, spleens were aseptically removed and separated into single cell suspensions. Splenocytes were treated with a solution containing 0.15 M ammonium chloride, 1 mM KHCO 3 , and 0.1 mM Na 2 EDTA, pH 7.2-7.4 to lyse the erythrocytes. Lymphocyte suspensions were adjusted to a concentration of 1 ϫ 10 6 cells/ml. One hundred microliters per well were aliquoted into 96-well plates. Purified particulate R. conorii antigen was added at concentrations of 1, 0.3, and 0.1 g/ml to triplicate wells. Plates were incubated at 37ЊC in an atmosphere containing 5% CO 2 . On day 5, 1 FIGURE 1. Rickettsia rickettsii fragments representing the genes encoding rOmpA and rOmpB were amplified by a polymerase chain reaction and cloned into mammalian and prokaryotic expression vectors. All fragments were tested as plasmid DNA vaccines. After immunization, four fragments (filled blocks) were shown to confer some degree of protection after a challenge with a lethal dose of R. conorii. Splenocytes from mice that received both DNA and recombinant protein preparations proliferated after antigen stimulation. Splenocytes from mice that received only DNA vaccine preparations containing the fragment rompB 2459-4123 also proliferated, although at a lower level, in response to antigen stimulation. A proliferative response was not observed after DNA immunizations containing the fragment rompA 4999-6710 .
Ci of 3 H-thymidine was added per well, and the plates were incubated overnight at 37ЊC. Cells were harvested into GF/ B (Packard Instruments Co., Meriden, CT) plates. After evaporation to dryness, 30 l of scintillation fluid was added to each well. 3 H-thymidine incorporation was determined in a beta counter (Top Count, Packard Instruments Co.). Lymphocyte proliferation was considered significant if the proliferation index (cpm of sample stimulated with antigen/cpm of sample without antigen) was greater than 3. IFN-␥ secretion was measured using a quantitative sandwich enzymelinked immunosorbent assay kit (R&D Systems, Minneapolis, MN). Supernatant samples of splenocytes (5 ϫ 10 6 /ml per well in a 24-well plate) were collected after stimulation with purified particulate R. conorii antigen for 72 hr. IFN-␥ concentration was determined following the manufacturer's instructions. Results reported are the average of triplicate samples. Standard deviations were determined using Microsoft (Redmond, WA) Excel. Differences among data sets were considered significant if P Յ 0.05; P values were determined using Student's t-test with Microsoft Excel. Antibody production was determined by indirect immunofluorescence assay. 38 
RESULTS
Cloning and expression of rickettsial fragments. DNA fragments representing the two major cell wall proteins of R. rickettsii ( Figure 1 ) were cloned into prokaryotic and mammalian expression vectors. Results are reported only for the fragments that conferred some degree of protection after challenge with a lethal dose of R. conorii. These fragments were rompA , rompB , and rompB . Homologous recombinant proteins (rOmpA , rOmpB , and rOmpB 754-1308 , respectively) were prepared using the pCR T7/ CT-TOPO vector (Invitrogen). Recombinant rickettsial proteins were detected by Western immunoblot using an antibody directed against the fusion His tag (Figure 2) .
Lymphocyte response. During the first set of experiments, spleens were harvested one day before challenge, and splenocytes were stimulated with three different doses of purified particulate R. conorii antigen. Splenocytes from mice that received only DNA vaccinations containing the fragment rompA 4999-6710 did not show higher levels of cell proliferation than the control groups ( Figure 3) . Only after the mice were boosted with the homologous recombinant protein rOmpA 1644-2213 did the proliferation index reach higher levels than the controls. Mice that received DNA vaccine containing the fragment rompB 2459-4123 showed higher levels of lymphocyte proliferation than the controls. These levels of proliferation were further increased after receiving the booster immunizations containing the homologous recombinant protein rOmpB . Secretion of IFN-␥ by lymphocytes from immunized mice correlated with the results of lymphocyte proliferation after antigen stimulation (Figure 4 ). Higher levels of IFN-␥ were observed only after mice received both DNA and recombinant protein preparations of the fragment rompA . Splenocytes from mice that received only DNA preparations containing the fragment rompB 2459-4123 secreted higher amounts of IFN-␥ than the controls, and again IFN-␥ secretion was further increased after receiving two booster immunizations containing the recombinant protein rOmpB .
During the second set of experiments, spleens were harvested for antigen stimulation studies at two time points during the course of the experiment. The first time point was after the second DNA immunization. IFN-␥ levels in the supernatants of these splenocytes cultured in the presence of R. conorii antigen were higher (P Յ 0.05) than the controls for all fragments except for one of the two mice immunized with the DNA fragment rompB 2459-4123 ( Figure 5A ). The second time point was one day before challenge with live R. conorii; at this point mice had received either both DNA and recombinant protein preparations or only recombinant protein. IFN-␥ secretion by antigen-stimulated lymphocytes was observed not only when mice received both DNA and recombinant protein but also when they had only received recombinant protein immunizations ( Figure 5B ). For fragment rompA 4999-6710, the IFN-␥ levels were higher after DNA immunization followed by booster immunization with recombinant protein. For the other two fragments, rompB and rompB 2459-4123 , the IFN-␥ levels were similar in animals immunized with the recombinant proteins regardless of receiving DNA immunizations or not. These results suggest that immunization with plasmids containing these two fragments did not enhance the T lymphocyte reactivity against rickettsiae.
Evidence of seroconversion was not observed during the course of any of the experiments except for the animals that received a sublethal dose of R. conorii.
Protective immunity. During the first set of experiments, mice received either three doses of DNA or three doses of DNA followed by two doses of homologous recombinant protein. Immunizations were carried out four weeks apart. Four weeks after the last immunization, animals were challenged with 3 LD 50 of R. conorii. Mice were observed daily for morbidity and mortality. Mice in all groups except for the positive immunity control group (convalescent from a sublethal dose of R. conorii) started to show signs of illness by day 4 post-inoculation. Mortality was observed on days 6 through 8. All mice that survived until day 9 recovered. Protection of all three mice per group was observed only when animals were immunized with DNA and boosted with the homologous recombinant protein and differed significantly (P ϭ 0.05) from both unvaccinated and animals vaccinated with DNA only. Immunization with only DNA preparations did not confer any protection (Table 3 ). In the second experiment, mice were immunized with DNA and boosted with the corresponding recombinant proteins. In addition, groups of mice that received only recombinant protein immunizations were included. The results (Table 4) corroborated our findings that protection was achieved when DNA immunizations are followed by booster immunizations with the homologous recombinant protein. Protection was also observed in animals that received only recombinant protein preparations. Although the percentage of survivors among the mice that received only recombinant protein preparations was lower (14-43%) than in the groups that received both DNA and recombinant protein preparations (60%), the differences were not statistically significant possibly because of the small number of animals in each group. Experiment three (Table 5) showed that indeed the combination of DNA and recombinant protein preparations conferred better protection than protein immunizations alone (37.5% versus 100%; P ϭ 0.028). Total protection (100%) was observed after DNA immunization with a mixture of the identified protective DNA fragments followed by booster immunizations containing a mixture of the corresponding recombinant proteins.
DISCUSSION
The development of vaccination strategies against intracellular parasites offers special challenges to scientists, and rickettsiologists are no exception. Despite the difficulties associated with their growth, preparation, and containment and the small number of scientists engaged in their study, three vaccine candidates have been developed against SFG rickettsioses. However, none of them have been proven to be sufficiently effective for current use. The reasons for their failure remain unknown and clearly reveal the need for more studies with focus on the mechanisms involved in the protective immune responses. It is known that cell mediated responses are the key effectors. Thus, an effective vaccine will be one that contains the immunostimulatory elements required to activate such types of responses. The vaccine will have to be designed in a way that ensures effective processing and presentation of epitopes to T lymphocytes by host cells. Until recently, live attenuated vaccines were the most effective approach to the development of protective vaccines, but safety issues, especially for pregnant women and immunocompromised hosts, remain a concern. The development of nucleic acid immunizations as vaccine strategies offers an attractive alternative for efficient antigen processing, presentation and priming of T lymphocytes. In addition to being safe, stable at room temperature and inexpensive to prepare, DNA vaccines are amenable to genetic manipulation, making it possible to include only the appropriate immunostimulatory sequences in a single vaccine preparation. Since the first demonstration of DNA vaccination as an efficient method of generating cytotoxic T lymphocyte activity and antibody secretion against the nuclear protein of influenza virus A, numerous studies of infectious diseases and cancer using plasmid DNA immunization have been reported. 39, 40 The novel strategy for vaccination known as ''primeboost'' (priming with DNA vaccines followed by boosting with attenuated recombinant viral vectors expressing the relevant antigens) has been shown to produce increased specific immune responses against the influenza virus, malaria, and human immunodeficiency virus. [41] [42] [43] [44] [45] In this study, the primeboost protocol used involved DNA vaccination followed by boosting with the corresponding recombinant peptide. This approach has been proven effective only in systems in which humoral responses play a crucial role. 46, 47 In this study, protection was achieved in the absence of antibodies after prime-boost using recombinant peptides.
During this study, we exploited DNA vaccine technology in an attempt to identify the immunostimulatory components of the two major outer proteins of SFG rickettsiae, rOmpA and rOmpB. As mentioned earlier, rickettsiae are intracellular organisms, and this condition presents different challenges for the immune system. Like most intracellular infections, rickettsioses are best controlled by mechanisms mediated by T lymphocytes with antibody playing a secondary role. Both rOmpA and rOmpB contain B and T lymphocyte epitopes and, thus, represent good candidates for a vaccine. In this study, one fragment from rOmpA and two fragments from rOmpB conferred protection against challenge with a lethal dose of R. conorii. Protection appeared to be better achieved among the groups that received both DNA and recombinant protein immunizations, although recombinant protein immunizations alone provided some protection. This situation suggests the presence of CD4 epitopes and an important role for CD4 T lymphocytes, since soluble proteins do not effectively enter the MHC Class I presentation pathway. 48 Total protection (100% of mice) was observed when vaccine was administered as a multivalent preparation of the protective DNA fragments and the corresponding recombinant proteins. The mixture was composed of the fragments described in this study and a fourth fragment, rompA . Fragment rompA 2176-3933 encodes the last six repeat units of Domain II followed by 368 basepairs of Domain III. (Figure  1 ). Protection can be achieved after plasmid DNA immunization with this fragment followed by a booster immunization with recombinant protein or by immunization with recombinant Mycobacterium vaccae organisms expressing the fragment followed by immunizations with the homologous recombinant protein (Crocquet-Valdes PA and others, unpublished data).
The fact that protection was achieved in the absence of detectable antibody corroborates the findings that humoral responses play a less important role in protective immunity. This result may be due to a Th1-biased response due to the coexpression of IL-12; therefore, the potential importance of B cell epitopes of rOmpA and rOmpB should not be discarded. 49 This study represents the first report of the use of recombinant plasmid DNA as vaccine strategy against rickettsial infections. The levels of protection reported are encouraging; more experiments intended to optimize the expression of the fragments and priming of T lymphocytes are currently taking place. These include the identification of CD8 T-lymphocyte epitopes at the oligopeptide level and the exploration of more effective means of antigen availability for processing and presentation.
In addition, the data presented represent the first reported evidence that rOmpB is an immunoprotective antigen of a SFG rickettsia and identify portions of rOmpA and rOmpB that stimulate protective immunity.
